Related references
Note: Only part of the references are listed.Annexin A2 Is a Molecular Target for TM601, a Peptide with Tumor-targeting and Anti-angiogenic Effects
Kamala Kesavan et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
PHSCNK-Modified and doxorubicin-loaded liposomes as a dual targeting system to integrin-overexpressing tumor neovasculature and tumor cells
Wenbing Dai et al.
JOURNAL OF DRUG TARGETING (2010)
A Novel Octreotide Modified Lipid Vesicle Improved the Anticancer Efficacy of Doxorubicin in Somatostatin Receptor 2 Positive Tumor Models
Junlin Zhang et al.
MOLECULAR PHARMACEUTICS (2010)
Specific Targeting of Brain Tumors with an Optical/Magnetic Resonance Imaging Nanoprobe across the Blood-Brain Barrier
Omid Veiseh et al.
CANCER RESEARCH (2009)
Levodopa delivery systems for the treatment of Parkinson's disease: An overview
J. Goole et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2009)
Neurodegenerative disorders and nanoformulated drug development
Ari Nowacek et al.
NANOMEDICINE (2009)
L-dopa therapy for Parkinson's disease: Past, present, and future
Toshiharu Nagatsu et al.
PARKINSONISM & RELATED DISORDERS (2009)
Fluorescence intensity and lifetime imaging of free and micellar-encapsulated doxorubicin in living cells
Xiaowen Dai et al.
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE (2008)
Tumor paint:: A Chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci
Mandana Veiseh et al.
CANCER RESEARCH (2007)
Drug targeting to the brain
A. G. de Boer et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2007)
Blood-brain barrier delivery
William M. Pardridge
DRUG DISCOVERY TODAY (2007)
Drug targeting to the brain
William M. Pardridge
PHARMACEUTICAL RESEARCH (2007)
Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation
Antonio Di Stefano et al.
JOURNAL OF DRUG TARGETING (2006)
Simultaneous determination of monoamines, their precursor amino acids, and related metabolites in mice brain by high-performance liquid chromatography with a coulometric electrode array system
ZD Yang et al.
ANALYTICAL LETTERS (2006)
Enhanced intracellular uptake of sterically stabilized liposomal doxorubicin in vitro resulting in improved antitumor activity in vivo
XB Xiong et al.
PHARMACEUTICAL RESEARCH (2005)
Protective effects of neuronal nitric oxide synthase inhibitor in mouse brain against MPTP neurotoxicity: an immunohistological study
H Watanabe et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2004)
Evaluation of rat striatal L-dopa and DA concentration after intraperitoneal administration of L-dopa prodrugs in liposomal formulations
A Di Stefano et al.
JOURNAL OF CONTROLLED RELEASE (2004)
Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice
A Leng et al.
BEHAVIOURAL BRAIN RESEARCH (2004)
Rapid intravenous loading of levodopa for human research: clinical results
KJ Black et al.
JOURNAL OF NEUROSCIENCE METHODS (2003)
Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin
SA Lyons et al.
GLIA (2002)
Drug and gene targeting to the brain with molecular Trojan horses
WM Pardridge
NATURE REVIEWS DRUG DISCOVERY (2002)
Parkinson disease: etiology, pathogenesis and future of gene therapy
BS Shastry
NEUROSCIENCE RESEARCH (2001)
Neurochemical findings in the MPTP model of Parkinson's disease
N Schmidt et al.
JOURNAL OF NEURAL TRANSMISSION (2001)
Biochemical and immunohistological changes in the brain of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse
T Araki et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2001)
Mouse models of α-synucleinopathy and Lewy pathology
B Sommer et al.
EXPERIMENTAL GERONTOLOGY (2000)